← Back to Clinical Trials
Recruiting NCT06663618

Short-term Glucocorticoid Combined with MMF for IgG4-RD

Trial Parameters

Condition IgG4-related Disease
Sponsor Wen Zhang
Study Type INTERVENTIONAL
Phase N/A
Enrollment 63
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2023-09-01
Completion 2025-03-01
Interventions
prednisonMycophenolate mofetil

Brief Summary

Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease

Eligibility Criteria

Inclusion Criteria: 1. 18-80 years old; 2. All patients must meet the comprehensive diagnostic criteria of IgG4-RD revised in Japan in 2020 or the classification criteria of IgG4-RD formulated by ACR/EULAR in 2019; 3. Active IgG4-RD (at least one organ has an IgG4-RD reaction score \>=2 at the time of enrollment.); 4. No previous medication or recurrence after withdrawal. Exclusion Criteria: 1. Combined with other autoimmune diseases as the main diagnosis. 2. Pregnant or lactating women 3. Patients with malignant tumor 4. Active bacterial, fungal, viral or mycobacterial infections. 5. Severe complications of important organs, and the expected survival time is less than 6 months.

Related Trials